Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.

V. R. Adams; T. Brenner

doi:10.1016/S1086-5802(15)30363-6

Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.

V. R. Adams
, T. Brenner

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.

Original language	English
Pages (from-to)	706-707
Number of pages	2
Journal	Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)
Volume	39
Issue number	5
DOIs	https://doi.org/10.1016/S1086-5802(15)30363-6
State	Published - 1999

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Pharmaceutical Science

Access to Document

10.1016/S1086-5802(15)30363-6

Cite this

@article{3f0474aa995d4945a1b23de94b799f8a,

title = "Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.",

abstract = "Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.",

author = "Adams, \{V. R.\} and T. Brenner",

year = "1999",

doi = "10.1016/S1086-5802(15)30363-6",

language = "English",

volume = "39",

pages = "706--707",

number = "5",

}

TY - JOUR

T1 - Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.

AU - Adams, V. R.

AU - Brenner, T.

PY - 1999

Y1 - 1999

N2 - Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.

AB - Oprelvekin decreases the need for platelet transfusion in nontransplant patients receiving myelosuppressive chemotherapy. Until pharmacoeconomics studies determine the most cost-effective strategy for use of oprelvekin, it is likely to be used primarily in patients receiving dose-intensive chemotherapy to maintain the high-dose regimen that may provide a survival advantage for the patient with cancer. Additional product information is available at www.ahp.com/products/neumega.htm.

UR - https://www.scopus.com/pages/publications/0033195411

UR - https://www.scopus.com/pages/publications/0033195411#tab=citedBy

U2 - 10.1016/S1086-5802(15)30363-6

DO - 10.1016/S1086-5802(15)30363-6

M3 - Article

C2 - 10533354

AN - SCOPUS:0033195411

SN - 1086-5802

VL - 39

SP - 706

EP - 707

JO - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)

JF - Journal of the American Pharmaceutical Association (Washington,D.C. : 1996)

IS - 5

ER -

Oprelvekin (Neumega), first platelet growth factor for thrombocytopenia.

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this